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Introduction: Robust and physiologically relevant infection models are required to
investigate pharmacokinetic–pharmacodynamic (PK/PD) correlations for anti-tuberculosis
agents at preclinical discovery.
Material and methods: This study has validated an inhalation-based rat infection model of
tuberculosis (TB) harboring mycobacteria in a replicating state that is suitable for investi-
gating pharmacokinetics and drug action of anti-tubercular agents. A reproducible and
actively replicating lung infection was established in Wistar rats by inhalation of a series
of graded inocula of Mycobacterium tuberculosis (MTB). Following an initial instillation
of 20(10) log 10 CFU/lung, MTB grew logarithmically for the first 3 weeks, and then entered
into a chronic phase with no net increase in pulmonary bacterial loads. Dose response of
front-line anti-TB drugs was investigated following pharmacokinetic measurements in
the plasma of infected rats.
Results: Rifampicin, Isoniazid, and pyrazinamide dosed per orally exhibited bactericidality
and good dose response with maximal effect of 6.77, 3.55, and 5.90 1.92 log 10 CFU
reductions in the lungs, respectively. In contrast, ethambutol was merely bacteriostatic
with 5.90 log 10 CFU/lung reduction and did not reduce the bacterial burden beyond the
initial bacterial loads present at the beginning of treatment in spite of high blood
ethambutol levels. Rat infection model with actively replicating bacilli provides a
physiologically distinct and pharmacologically relevant model that can be exploited to
distinguish investigational compounds into bacteriostatic or bactericidal scaffolds.
Conclusions: The present study proposes that this rat infection model – although it needs
more drug substance – can be used in early discovery settings to investigate the
pharmacology of novel anti-tubercular agents for the treatment of active pulmonary
tuberculosis.
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